Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Rulebook #10. If a company has changed therapeutic focus more than twice and doesnt have a marketed drug and has been public more than 5 years, run.

Fair rule -- but in defense of the timelines, I would just note that with gene therapy we are in new world and approval times may stretch. We are talking about in-vivo gene editing of humans, a genetic change that could be with them for life, not a drug that will clear their system in a short time. FDA allowing testing of 1,2, 5 patients at a time. 5 year rule may not work in this space.

Another risks with the gene editing from investment standpoint, is it seems like many companies going after similar well-understood single gene issues, e.g. hemophilia, sickle cell, beta thalassemia. They may be on track to validate their platform but may not be first to market and if not best in class, may not get to market at all.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.